Updates on the management of Glioblastoma

52.9K

views

106

authors

17

articles

Updates on the management of Glioblastoma

52.9K

views

106

authors

17

articles

Editorial

05 February 2025

Editorial: Updates on the management of glioblastoma

Dorota Lubanska

,

Sameh Elmorsy Hassan

,

Lisa A. Porter

and

Mohamed A.R. Soliman

1,088 views

0 citations

Editors

5

Mohamed Soliman

Cairo University

University of Windsor

Robert Fenstermaker

Roswell Park Comprehensive Cancer Center, University at Buffalo

Sameh Elmorsy Hassan Elmorsy

Cairo University

DOROTA LUBANSKA

University of Windsor

Impact

About

Glioblastoma is the most common primary malignant brain tumor, representing approximately 48% of all primary central nervous system malignant tumors. Despite advances in multidisciplinary treatment for glioblastoma including surgery, radiation therapy, systemic therapy such as chemotherapy, locoregional therapies, immunotherapies, other targeted therapies, and supportive care, the overall prognosis is poor, with an average survival of 14 months. Furthermore, it is associated with a progressive decline in quality of life and neurologic function impacting the patients and their families. The new era of molecular biology and targeted therapies such as immunotherapy may have a lot of promising chances in developing more effective and tolerable treatments to combat this deadly disease.

This Research Topic will focus on the management of glioblastoma in the adult population from different perspectives such as chemotherapy, radiotherapy, immunotherapy, glioma stem cell therapy, nanotechnology, endovascular treatment, and novel surgical management tools and concepts. This includes basic science and clinical studies.

For bioinformatics/in silico studies (including but not limited to candidate biomarkers), there must be independent validation in clinical samples obtained from participating institutions and/or functional validation in at least two recognized glioblastoma cell lines in vitro and/or in vivo.

Glioblastoma is the most common primary malignant brain tumor, representing approximately 48% of all primary central nervous system malignant tumors. Despite advances in multidisciplinary treatment for glioblastoma including surgery, radiation therapy, systemic therapy such as chemotherapy, locoregional therapies, immunotherapies, other targeted therapies, and supportive care, the overall prognosis is poor, with an average survival of 14 months. Furthermore, it is associated with a progressive decline in quality of life and neurologic function impacting the patients and their families. The new era of molecular biology and targeted therapies such as immunotherapy may have a lot of promising chances in developing more effective and tolerable treatments to combat this deadly disease.

This Research Topic will focus on the management of glioblastoma in the adult population from different perspectives such as chemotherapy, radiotherapy, immunotherapy, glioma stem cell therapy, nanotechnology, endovascular treatment, and novel surgical management tools and concepts. This includes basic science and clinical studies.

For bioinformatics/in silico studies (including but not limited to candidate biomarkers), there must be independent validation in clinical samples obtained from participating institutions and/or functional validation in at least two recognized glioblastoma cell lines in vitro and/or in vivo.

Share

Editors

Mohamed Soliman

Cairo University

University of Windsor

Robert Fenstermaker

Roswell Park Comprehensive Cancer Center, University at Buffalo

Sameh Elmorsy Hassan Elmorsy

Cairo University

DOROTA LUBANSKA

University of Windsor

Impact

52,899 Total views

34,251 Article views

17,454 Article downloads

1,194 Topic views

Published In

Journal Thumbnail

Frontiers in Neurology

Neuro-Oncology and Neurosurgical Oncology

Journal Thumbnail

Frontiers in Pharmacology

Pharmacology of Anti-Cancer Drugs

Journal Thumbnail

Frontiers in Oncology

Neuro-Oncology and Neurosurgical Oncology, Pharmacology of Anti-Cancer Drugs

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic